Significance of aquaporin-4 antibodies detection in diagnosis and treatment of neuromyelitis optica spectrum disorders
10.3760/cma.j.issn.1671-8925.2014.09.011
- VernacularTitle:水通道蛋白4抗体测定对视神经脊髓炎谱系疾病的意义
- Author:
Daqi ZHANG
1
;
Li YANG
;
Chunsheng YANG
;
Ting LI
;
Yu WANG
;
Hui ZHAI
;
Fudong SHI
Author Information
1. 300052天津,天津医科大学总医院神经内科,天津市神经病学研究所神经免疫实验室
- Keywords:
Neuromyelitis optica;
Aquaporin-4 antibody;
Cell-based immunofluorescence assay
- From:
Chinese Journal of Neuromedicine
2014;13(9):914-918
- CountryChina
- Language:Chinese
-
Abstract:
Objective To test the level of aquaporin-4 (AQP4) antibody and assess the frequency and specificity of AQP4 antibodies in patients with neuromyelitis optica spectrum disorders (NMOSDs).Methods One hundred and fifty-three patients with demyelinating disease of the central nervous system,admitted to our hospital from May 2007 to May 2012,were chosen in our study; of them,102 had NMOSDs; AQP4 antibodies in the sera of these 102 patients were detected by cell-based immunofluorescence assay (CBA); the distinctive features of NMOSDs by autoantibodies status (AQP4 antibody-positive or antibody-negative) were analyzed retrospectively.Results The sensitivity and specificity of CBA assay for detecting AQP4 antibodies were 83.3％ and 100％,respectively.In patients with positive AQP4 antibodies,the female one took 78.8％,while in patients with negative AQP4 antibodies,the female one only took 28.6％; significant difference was noted between the two (P=0.007); the patients with both AQP4 antibody-positive and other systemic autoimmune diseases showed higher expanded disability status scale scores at the disease onset (5.9±2.0) as compared with the patients only with AQP4 antibody-positive (4.2±1.9,t=3.806,P=0.033); AQP4 antibody deduced even lost during the remission stage,and immunosuppressant medicine could remove the AQP4 antibody.Conclusion Testing for AQP4 antibodies is helpful for the differential diagnosis between NMOSDs and multiple sclerosis,and also useful for predicting the relapse and treating of NMOSDs.
